Healthcare / BiotechnologyNasdaqCM
$9.67
-0.57 (-5.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-107822.00 · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$87M
P/E
N/A
•EV/EBITDA
45.3x
↑ROE
-3.8%
↓Gross Margin
41.4%
↓Debt/Equity
0.49
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
4.4%
FCF / Net income
-1.18x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $27.6M · net income $-1.0M · FCF $1.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $27.6M | $27.6M | $26.5M | $17.5M | $18.6M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Income | $-1.0M | $-1.0M | $-2.2M | $-5.8M | $-2.5M | $-78292.00 | $-1.0M | $-1.3M | $-2.3M | $-168147.00 | $508448.00 | $1.2M | $-167159.00 | $117395.00 | $89512.00 | $-409510.00 | $-384684.00 | $-216493.00 |
| EBITDA | $2.1M | $2.1M | $1.1M | $-2.6M | $349986.00 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS | — | — | -0.26 | -0.75 | -0.32 | -0.01 | -0.14 | -0.19 | -0.42 | -0.03 | 0.12 | 0.38 | -0.06 | 0.04 | 0.03 | -0.14 | -0.13 | -0.07 |
| Gross Margin | 41.4% | 41.4% | 30.0% | 22.1% | 41.2% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 6.0% | 6.0% | -6.2% | -32.9% | -12.4% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | -3.8% | -3.8% | -8.1% | -33.1% | -13.4% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.49 | 0.49 | 0.55 | 0.67 | 0.41 | 0.02 | 0.34 | 0.29 | 0.43 | 0.38 | — | — | — | 0.10 | 0.13 | 0.15 | — | — |
| Current Ratio | 4.82 | 4.82 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $1.2M | $1.2M | $-107822.00 | $-6.6M | $-5.5M | $-1.7M | $-2.8M | $-1.2M | $-2.4M | $-16.6M | $-3.8M | $181047.00 | $-1.2M | $500963.00 | $68995.00 | $-281050.00 | $-925160.00 | $-569213.00 |
| Returns | ||||||||||||||||||
| ROE | -3.8% | -3.8% | -7.8% | -23.1% | -8.2% | -0.2% | -3.6% | -4.5% | -10.7% | -0.7% | 2.6% | 11.4% | -1.8% | 1.2% | 1.0% | -4.5% | -4.1% | -2.2% |
| Valuation | ||||||||||||||||||
| EV/EBITDA | 45.26 | 45.26 | 50.06 | — | 160.74 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 3.23 | 3.23 | 1.53 | 1.48 | 1.63 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 4.3% | 4.3% | 51.6% | -5.9% | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS Growth | — | — | 65.3% | -134.4% | — | 92.9% | 26.3% | 54.8% | -1300.0% | -125.0% | -68.4% | 733.3% | -250.0% | 33.3% | 121.4% | -7.7% | -85.7% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+51.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.26 → n/d
Residual
+51.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.